Wednesday, August 15, 2007 9:35:23 AM
>> companies with interesting new technologies should not compound their risk by applying their technology to difficult or intractable targets
And perhapse that's exactly why GTCB choose not to lead with the DIC indication?
First establish ATryn as a valid biologic via the antithrombin hereditary deficiency trials, then expand to DIC; seams like the exact stratagy you would like
And perhapse that's exactly why GTCB choose not to lead with the DIC indication?
First establish ATryn as a valid biologic via the antithrombin hereditary deficiency trials, then expand to DIC; seams like the exact stratagy you would like
Join the InvestorsHub Community
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
